Body fluids

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana

Thursday, August 6, 2020 - 5:01pm

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.

Key Points: 
  • BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.
  • Plasma is a lifeline for thousands of people with rare, chronic and complex diseases, and we are excited to open the first BioLife plasma collection center in Louisiana.
  • To learn more about BioLife Plasma Services, the donation process, and to schedule an appointment, please visit the BioLife website.
  • BioLife Plasma Services is an industry leader in the collection of high-quality plasma that is processed into life-saving plasma-based therapies.

Haemonetics First Quarter Fiscal 2021 Earnings Release Available on Investor Relations Website

Tuesday, August 4, 2020 - 11:00am

The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EDT August 4, 2020.

Key Points: 
  • The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EDT August 4, 2020.
  • The call can be accessed with the following information:
    U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
    Conference ID required for access: 3897757
    A live webcast of the call can be accessed on Haemonetics' Investor Relations website.
  • Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.
  • To learn more about Haemonetics, visit our website at http://www.haemonetics.com .

Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020

Saturday, August 1, 2020 - 4:00pm

Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.
  • These data highlight the gaps in diagnosis and treatment still prevalent in the bleeding disorders community today, and spotlight opportunities for Takeda to better support these patients.
  • We have 70+ years of experience driving innovation for patients and a broad portfolio of 11 products across multiple bleeding disorders.
  • Our experience as leaders in hematology means we are well prepared to meet todays needs as we pursue future developments in the treatment of bleeding disorders.

eTrueNorth Actively Participating in “The Fight Is In Us” Campaign Encouraging COVID-19 Survivors to Donate Plasma

Friday, July 31, 2020 - 3:49pm

This broad-based national campaign will encourage all individuals who have recovered from COVID-19 to donate plasma that may help others diagnosed with the virus.

Key Points: 
  • This broad-based national campaign will encourage all individuals who have recovered from COVID-19 to donate plasma that may help others diagnosed with the virus.
  • A COVID-19 survivors convalescent plasma may be transfused into patients struggling against the virus or used to develop another potential treatment.
  • eTrueNorth will be asking those who have had a positive test result from one of the drive-through specimen collection sites to consider donating plasma by visiting https://thefightisinus.org/.
  • By partnering with national pharmacy brands, eTrueNorth takes full advantage of its Voucher Solution to make testing available to those in need.

Plasma Therapy Global Market Report 2020-30: Covid 19 Growth and Change

Thursday, July 30, 2020 - 3:40pm

The global plasma therapy market is expected to grow from $187.67 million in 2019 to $246.95 million in 2020 at a compound annual growth rate (CAGR) of 31.6%.

Key Points: 
  • The global plasma therapy market is expected to grow from $187.67 million in 2019 to $246.95 million in 2020 at a compound annual growth rate (CAGR) of 31.6%.
  • The plasma therapy market consists of revenues generated by the companies that are engaged in selling and manufacturing plasma therapy products and related services.
  • Plasma therapy is a technique where high concentrations of plasma are transfused or injected to patients to facilitate the healing process.
  • Convalescent plasma therapy, to treat patients suffering from COVID 19 is a leading trend in the plasma therapy market.

Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems

Thursday, July 30, 2020 - 1:30pm

Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets.
  • The Hong Kong Red Cross BTS is the only public institution providing blood to all hospitals, public and private, in Hong Kong.
  • The Hong Kong Red Cross BTS is a member of the influential Asia Pacific Blood Network (APBN) and a key opinion leader globally.
  • The tender award builds upon the prior experience of the Hong Kong Red Cross BTS with the INTERCEPT Blood System for platelets.

Novalis Invests in Enzyre to Support Development of Enzypad, a Breakthrough Hand-Held Diagnostic and Monitoring Device

Monday, July 27, 2020 - 7:00am

The first application of Enzypad will revolutionize monitoring of hemophilia by providing a real-time picture of a patients blood coagulation status.

Key Points: 
  • The first application of Enzypad will revolutionize monitoring of hemophilia by providing a real-time picture of a patients blood coagulation status.
  • In December 2019, Enzyre signed a collaboration with Takeda for the development of Enzypad in congenital bleeding disorders, validating this innovative approach.
  • Dirk Pollet, CEO of Enzyre commented: We are pleased to welcome Novalis Biotechnology Incubation to our investor base.
  • Enzyre, based in Nijmegen, The Netherlands, is a spin-out from Radboud University Medical Center, developing Enzypad, a near patient diagnostic and monitoring device initially focused on blood coagulation.

Insights on the Plasma Fractionation Global Market to 2027 - Featuring CSL, Green Cross & Grifols Among Others - ResearchAndMarkets.com

Wednesday, July 22, 2020 - 1:51pm

The "Plasma Fractionation - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Plasma Fractionation - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 188-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • This segment currently accounts for a 24.1% share of the global Plasma Fractionation market.
  • In the global Albumin segment, USA, Canada, Japan, China and Europe will drive the 5% CAGR estimated for this segment.

Therapeutic Solutions International Reports QuadraMune™ Inhibits Inflammation Induced Blood Clotting: Possible Implication for Ongoing Covid-19 Prevention Clinical Trial?

Monday, July 13, 2020 - 2:35pm

Inhibition of this coagulation-promoting molecule, called Tissue Factor, was synergistic with all four ingredients of QuadraMune when combined.

Key Points: 
  • Inhibition of this coagulation-promoting molecule, called Tissue Factor, was synergistic with all four ingredients of QuadraMune when combined.
  • "Myself and my colleagues are puzzled by the abnormal blood clots that are found throughout the body of COVID-19 patients.
  • We are seeing strokes in patients in their 30s, and abnormal blood coagulation pathology that normally is restricted to patients with hematological abnormalities.
  • Importantly, the Company previously reported that QuadraMune inhibits production of inflammatory molecules from the blood of healthy volunteers while stimulating natural killer cells6.

Black Hills Life Flight Adds Blood and Plasma to All Emergency Air Medical Transports

Monday, July 13, 2020 - 2:00pm

Carrying blood and plasma during air medical transports is vital for optimal patient outcomes.

Key Points: 
  • Carrying blood and plasma during air medical transports is vital for optimal patient outcomes.
  • Black Hills Life Flight is proud to add blood and plasma to flights to enhance our ability to care for patients, said Darryl Crown, regional business account executive for Air Methods and Black Hills Life Flight.
  • Adding blood and plasma to Black Hills Life Flight helicopters and fixed-wing aircraft will allow emergency personnel to provide additional lifesaving care.
  • With nearly 40 years of air medical experience, Air Methods is the preferred partner for hospitals and one of the largest community-based providers of air medical services.